Grünenthal Expands Bond Offering by €175 Million

Grünenthal, a leading pharmaceutical company in pain management, has announced a €175 million extension of its Senior Secured Notes due 2031, increasing the total to €675 million. The Additional Notes carry the same 4.625% interest rate as the original issue and are expected to be settled on November 26, 2025.

The notes were offered under Regulation S, outside the United States. Initially issued with a temporary ISIN, they will become fully fungible with existing notes after a 40-day compliance period. Proceeds will address existing liabilities and support corporate activities, including potential acquisitions.

The company also pre-announced Q3 financial results, forecasting revenues of €1,351 million and Adjusted EBITDA of €404 million, aligned with market expectations.